NHS England is 'failing rare disease patients,' charity says

6 December 2016

Changes in the way that NHS England commissions specialized treatments have been called for by a charity working to improve the lives of patients and families affected by genetic conditions.

On Sunday NHS England announced its decision to routinely commission 10 new such treatments, part of the process for the 2016-17 financial year, and Genetic Alliance UK has stressed that, regardless of legal challenge that has been brought in the intervening time, this decision should have taken place before April of this year.

"We are extremely concerned about the delays in getting to this point and the lack of transparency"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK